ClinicalTrials.gg

Program

denifanstat

Also written as “Denifanstat”, “ASC40” and “TVB-2640”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Acne Vulgaris · Glioblastoma · Neoplasms, led by 2 companies.

Furthest: phase 3, since Sep 10, 202415 company-led studies, 2 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sagimet Biosciences91 open or runningphase 3since Sep 10, 2024Aug 18, 2014Aug 2027phase 3 · NCT07863193
Ascletis Pharma61 open or runningphase 3since Oct 26, 2021Apr 14, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 18, 2014First study: phase 1 study in NeoplasmsNew to Sagimet BiosciencesSagimet Biosciences · NCT02223247 · 180 enrolled · United States, United Kingdom
  2. Apr 24, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseSagimet Biosciences · NCT03938246 · 142 enrolled · United States, China
  3. Apr 14, 2020Ascletis Pharma's first study: phase 1 study in HealthyNew to Ascletis PharmaAscletis Pharma · NCT04352361 · 34 enrolled · China
  4. Apr 9, 2021Phase 1 study in HealthyAscletis Pharma · NCT04843449 · 24 enrolled · China
  5. May 20, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseSagimet Biosciences · NCT04906421 · 168 enrolled · United States, Canada, Poland and more
  6. Oct 26, 2021Phase 3 study in GlioblastomaAscletis Pharma · NCT05118776 · 136 enrolled · China
  7. Oct 26, 2021Phase 2 study in Acne VulgarisAscletis Pharma · NCT05104125 · 180 enrolled · China
  8. Dec 12, 2022Phase 1 study in Healthy VolunteersSagimet Biosciences · NCT05657834 · 8 enrolled · United States
  9. Apr 17, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseSagimet Biosciences · NCT05835180 · 48 enrolled · United States, Hungary
  10. Dec 14, 2023Phase 3 study in Acne VulgarisAscletis Pharma · NCT06192264 · 480 enrolled · China
  11. Jan 31, 2024Phase 3 study in Acne VulgarisAscletis Pharma · NCT06248008 · 240 enrolled · China
  12. Sep 10, 20242 phase 3 studies in Non-alcoholic Fatty Liver DiseaseSagimet Biosciences · NCT06692283, NCT06594523
  13. Oct 8, 2025Phase 1 study in HealthySagimet Biosciences · NCT07216313 · 40 enrolled · United States
  14. Oct 2, 2026Phase 3 study in Acne VulgarisSagimet Biosciences · NCT07863193 · 800 planned · United States

Ahead

  1. Aug 2027Primary completion: phase 3 study in Acne VulgarisSagimet Biosciences · NCT07863193

TargetBeta

FASN →read by rule
“An orally bioavailable fatty acid synthase (FASN) inhibitor, ”NCIt, by rule

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07863193Acne Vulgaris · United States3RecruitingSagimet BiosciencesAug 2027800
NCT07216313Healthy · United States1CompletedSagimet BiosciencesOct 20, 202540
NCT06692283Non-alcoholic Fatty Liver Disease3WithdrawnSagimet BiosciencesJun 20260
NCT06594523Non-alcoholic Fatty Liver Disease3WithdrawnSagimet BiosciencesDec 20300
NCT06248008Acne Vulgaris · China3CompletedAscletis PharmaNov 12, 2025240
NCT06192264Acne Vulgaris · China3CompletedAscletis PharmaMay 19, 2025480
NCT05835180Non-alcoholic Fatty Liver Disease · United States, Hungary1CompletedSagimet BiosciencesDec 18, 202348
NCT05657834Healthy Volunteers · United States1CompletedSagimet BiosciencesDec 21, 20228
NCT05118776Glioblastoma · China3Active, not recruitingAscletis PharmaJun 2025136
NCT05104125Acne Vulgaris · China2CompletedAscletis PharmaApr 10, 2023180
NCT04906421Non-alcoholic Fatty Liver Disease · United States, Canada, Poland and more2CompletedSagimet BiosciencesOct 2, 2023168
NCT04843449Healthy · China1CompletedAscletis PharmaMay 6, 202124
NCT04352361Healthy · China1CompletedAscletis PharmaApr 29, 202034
NCT03938246Non-alcoholic Fatty Liver Disease · United States, China2CompletedSagimet BiosciencesOct 2, 2021142
NCT02223247Neoplasms · United States, United Kingdom1CompletedSagimet BiosciencesJun 2017180

How it is read

Names in the registry

  • “Denifanstat”, 3 entries
  • “ASC40”, 3 entries
  • “TVB-2640”, 3 entries
  • “ASC40 25mg”, 1 entry
  • “ASC40 50mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.